Molecular profiling and management of mantle cell lymphoma.

Molecular profiling and management of mantle cell lymphoma. Hematology Am Soc Hematol Educ Program. 2019 Dec 06;2019(1):30-40 Authors: Ruan J Abstract Mantle cell lymphoma (MCL) is a distinct subtype of B-cell non-Hodgkin lymphoma characterized by the t(11;14)(q13;q32) translocation leading to cyclin D1 overexpression and cell cycle dysregulation. Molecular profiling with gene expression and deep sequencing analyses has identified genomic and epigenomic alterations in pathways regulating the cell cycle, DNA damage response, proliferation, and survival, which contribute to disease progression with important prognostic and therapeutic implications. Clinically, the nonnodal MCL subset is notable for leukemic presentation, indolent behavior, and association with hypermutated IGHV and lack of SOX11 expression, which differentiates it from the conventional nodal MCL. In addition to the Mantle Cell Lymphoma International Prognostic Index score and proliferative gene signatures, 17p/TP53 and 9p/CDKN2A alterations, and genomic complexity have emerged as clinically useful biomarkers of high-risk disease associated with aggressive disease behavior, resistance to chemotherapy, and poor overall survival. Although intensive chemoimmunotherapy regimens that incorporate high-dose cytarabine and stem cell transplantation have improved survival in young and fit MCL patients, the introduction of Bruton tyrosine kinase inhibitors and other novel agents has made effective out...
Source: Hematology ASH Education Program - Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research

Related Links:

Publication date: Available online 20 January 2020Source: Clinica Chimica ActaAuthor(s): Hanna AntushevichAbstractFecal microbiota transplantation (FMT) is the introduction (transplantation) of gut microbiota obtained from the faeces of a healthy donor into the patient’s gastrointestinal tract. Most often, such therapy is used the treatment of gastrointestinal diseases caused by the activity of pathogenic or conditionally pathogenic microorganisms, however, recently an increasing number of studies have reported the use of fecal microbiota transplantation for the treatment of diseases such as metabolic syndrome, diabe...
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
Authors: Harrington P, Radia D, de Lavallade H Abstract INTRODUCTION: The outlook for patients with chronic myeloid leukaemia (CML) has changed dramatically with the development of tyrosine kinase inhibitors (TKIs) with the current treatment goal for many patients being to obtain a durable deep molecular remission, discontinue TKI therapy and remain treatment-free.Areas covered: In this article the authors review the data from the major TKI discontinuation studies, explore potential predictors of discontinuation outcome and look at possible mechanisms to explain the variable outcomes following TKI discontinuation i...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
Authors: Tönshoff B Abstract Introduction: The goal of immunosuppressive therapy post-transplantation in pediatric renal transplant recipients is to prevent acute and chronic rejection while minimizing drug side effects. Most therapies alter immune response mechanisms but are not immunologically specific, and a careful balance is required to find the dose that prevents rejection of the graft, while minimizing the risks of over-immunosuppression leading to infection and cancer.Areas covered: This review article focuses on immunosuppressive therapy in pediatric renal transplant recipients, but many aspects can b...
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research
ConclusionBM-MSCs delivered miR-222-3p via exosomes to inhibit cell proliferation and promote cell apoptosis by targeting IRF2 and negatively regulating IRF2/INPP4B signaling in THP-1 cells.
Source: Molecular and Cellular Probes - Category: Molecular Biology Source Type: research
Those who consume up to 20 drinks per week are less likely to develop chronic kidney disease than never drinkers, but authors warn"potential benefits" of alcohol must be weighed against"harms."Medscape Medical News
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Nephrology News Source Type: news
CD19 CAR T-cell (CAR-19) therapy have elicited great clinical responses in B-cell malignancies. However, CD19-negative relapse has emerged as a major challenge for the long-term disease control post CAR-19 therapy and conferred a dismal outcome to these pts. Recently, co-targeting of CD19/CD20, CD19/CD22 or CD19/CD123 has been proposed as a strategic approach to overcome antigen loss relapse after CAR-19 therapy. However, the infusion scheme has not yet been defined, the efficacy to avoid antigen escape has not been tested, and its toxicity remains to be assessed. Furthermore, the impact of genetic abnormalities on the out...
Source: Blood - Category: Hematology Authors: Tags: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster I Source Type: research
IntroductionFL is characterized by the translocation t(14;18), resulting in constitutive overexpression of the key anti-apoptotic protein BCL2. Ven, a selective, potent oral inhibitor of BCL2, has shown profound efficacy combined with anti-CD20 antibodies in chronic lymphocytic leukemia and is in development for treating other hematologic malignancies, including non-Hodgkin lymphoma (NHL). Preclinical and early clinical data in indolent NHL suggest addition of Ven to R or chemo may improve efficacy. The open-label CONTRALTO study (NCT02187861) assessed efficacy and safety of a chemo-free regimen with Ven+R or randomized Ve...
Source: Blood - Category: Hematology Authors: Tags: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma-Clinical Studies: Poster I Source Type: research
Mantle cell lymphoma (MCL) accounts for approximately 6% of all Non-Hodgkin lymphoma (NHL) with a median age at presentation of around 70 years. It is characterised by the t(11;14)(q13:32) translocation which leads to overexpression of cyclin D1 resulting in subsequent dysregulation of the cell cycle and of several intracellular survival pathways. Although the survival of MCL patients has been demonstrated to have improved over the last decade it remains incurable, typically relapsing multiple times with increasingly chemotherapy refractory disease.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Abstract Characteristic chromosomal translocations are found to be associated with subtypes of B-cell non-Hodgkin lymphoma (NHL), for example t(8;14)(q24;q32) and Burkitt lymphoma, t(14;18)(q32;q21) and follicular lymphoma, and t(11;14)(q13;q32) in mantle cell lymphoma. Only few recurrent cytogenetic aberrations have been identified in the T-cell NHL and the best known is the ALK gene translocation t(2;5)(p23;q35) in anaplastic large cell lymphoma. Since lymph node or other tissue is seldom submitted for conventional cytogenetics study, alternative approaches for translocation detection are polymerase chain reacti...
Source: Mol Biol Cell - Category: Molecular Biology Authors: Tags: Methods Mol Biol Source Type: research
Conclusion: This is the first report of development of a variant t(4;12;6) and fusion PDGFRα/ETV6 fusion that developed during transition from CMML to AML. Despite PDGFRα/ETV6 fusion the patient did not respond to imatinib.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Genome variation profiling by array Homo sapiens Source Type: research
More News: Chemotherapy | Education | Genetics | Hematology | Hodgkin's Disease | Leukemia | Lymphoma | Non-Hodgkin's Lymphoma | Stem Cell Therapy | Stem Cells | Translocation | Transplants | Universities & Medical Training